Sai Parenteral’s IPO
₹372 – ₹372 · Issue Size ₹409 CrIPO Overview
Business Model
- Diversified generic formulations player with an established track record
- Strategically located and accredited Manufacturing Facilities
- Strong focus on CDMO business
- Well-established sales network in India and overseas
- Track record of value-accretive acquisitions
- Experienced Promoters and Senior Management with extensive domain knowledge
- For further details, see
IPO Timeline
Objects of the Issue
The Net Proceeds are proposed to be used in the manner set out in in the following table: (₹ in million) Sr. Particulars Estimated Amount 1. Capacity expansion and upgradation of manufacturing facilities 1,107.95 2.
Strengths & Weaknesses
Strengths
- Diversified generic formulations player with an established track record
- Strategically located and accredited Manufacturing Facilities
- Strong focus on CDMO business
- Well-established sales network in India and overseas
- Track record of value-accretive acquisitions
- Experienced Promoters and Senior Management with extensive domain knowledge
- For further details, see
Management & Promoters
Peer Comparison
| Company | P/E | EPS |
|---|---|---|
| Sai Parenteral’s IPO | — | — |
| Solitaire Corporate Park Bldg | — | — |
| Telephone: + | 91.0x | — |
Pre-IPO Financials
| Period | Revenue (Cr) | PAT (Cr) | Net Worth (Cr) | Total Assets (Cr) |
|---|---|---|---|---|
| September 2025 | ₹86.12 Cr | ₹202.3 Cr | — | ₹3.1 Cr |
| March 2025 | ₹23.79 Cr | ₹11.16 Cr | — | ₹202.3 Cr |
| March 2024 | ₹32.37 Cr | ₹19.91 Cr | — | ₹0.4 Cr |
| March 2023 | ₹66.01 Cr | ₹12.56 Cr | — | ₹0.6 Cr |
| 2015 | ₹3.93 Cr | ₹7.25 Cr | — | — |
About
Sai Parenteral’s Ltd., founded in 2001, is one of the leading pharmaceutical companies focused on R&D and manufacturing of pharmaceutical products. The firm operates in 2 main business areas: makes and sells its own branded medicines, and also manufactures medicines for other companies internationally. Its product offerings include a wide range of medicines for various health conditions, like cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology,
Key Regulations and Policies in India", "Statement of Possible Tax Benefits", "Financial Information", History and Certain Corporate Matters" "Objects of the Offer" "Basis for Offer Price", "Outstanding Litigation and Material Developments" and
| Exchange | NSE |
| Issue Type | mainboard |
| Face Value | ₹5 per share |
Documents
rupiya.io is for research and education only. IPO data is sourced from public disclosures (DRHP/RHP). Not investment advice. Validate with SEBI-regulated disclosures before acting.